In a retrospective cohort study of a registry of Danish patients aged 40 years and older who underwent total joint replacement in 1998–2007, starting therapy with oral bisphosphonates after arthroplasty seemed to improve implant survival. Among bisphosphonate users, 27 out of 1,558 (1.73%) underwent revision surgery during the study follow-up period (median 2.61 years), compared with 399 of 8,966 (4.45%) matched non-users.
References
Prieto-Alhambra, D. et al. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheum. 10.1002/art.38789
Rights and permissions
About this article
Cite this article
Bisphosphonates reduce risk of revision surgery. Nat Rev Rheumatol 10, 512 (2014). https://doi.org/10.1038/nrrheum.2014.131
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.131